Author Interviews, Cancer Research, Cannabis / 12.06.2026

Editor's Note: Cannabis laws and regulations vary by country, state, and territory. This interview is for educational purposes only. Cannabis products discussed here are not endorsed by MedicalResearch.com. Patients should consult their oncologist or healthcare provider before using any cannabis or cannabinoid product, particularly during cancer treatment. Cannabis products should not be used while driving, by children, if pregnant, nursing or planning to become pregnant or mixed with other substances that can affect cognition. Cannabis products may also be contraindicated in other medical conditions or situations.

cannabis-and-cancer-posterMedicalResearch.com Interview with: Raphael E. Cuomo, PhD Associate Professor University of California, San Diego Developer and Host, Cannabis and Cancer (Apple TV Documentary)  
MedicalResearch.com: What is the background for this documentary? What are the primary components of cannabis plants? Response: I created Cannabis and Cancer because cannabis is now widely discussed by patients, clinicians, policymakers, and the general public, but there is still a lot of confusion about what the science actually says. Much of the public conversation treats cannabis as either broadly harmful or broadly beneficial. The reality is more complex. The documentary is meant to separate questions that are often conflated: whether cannabis exposure may influence the risk of developing cancer, whether cannabis use may affect cancer treatment or symptoms, and whether it may influence survival after a cancer diagnosis. These are very different scientific questions, and each one requires a different type of evidence. Cannabis plants contain many biologically active compounds. The most widely discussed are cannabinoids, especially THC and CBD. THC is the main intoxicating compound and is responsible for many of the psychoactive effects. CBD is not intoxicating in the same way, but it still has biological effects. Cannabis also contains other cannabinoids, terpenes, flavonoids, and plant compounds that may influence how different products affect the body.
Author Interviews, End of Life Care, JAMA / 03.10.2016

MedicalResearch.com Interview with: [caption id="attachment_28516" align="alignleft" width="155"]Joshua R. Lakin, MD Instructor in Medicine Harvard Medical School Dana Farber Cancer Institute Dr. Joshua Lakin[/caption] Joshua R. Lakin, MD Assistant Professor of Medicine Harvard Medical School Dana Farber Cancer Institute MedicalResearch.com: What is the background for this study? What are the main findings? Response: Research has increasingly shown the benefits of early palliative care interventions, especially in those around communication about patient goals and preferences in serious illness. These benefits include improved quality of life and psychological outcomes for patients as well as eased bereavement and decision making for loved ones. We have a large gap to fill in initiating early goals and values conversations with our patients and there are a myriad of systems failures and clinician barriers that do not allow us to do this work in a timely and effective way. Doing so with limited resources, both in specialty palliative care and in the many frontline clinicians doing this work, requires targeting our resources carefully. Doing these conversations earlier means identifying patients upstream, before they are in the last days of life. The Surprise Question – “Would you be surprised if this patient died in the next year?” – has emerged as an attractive option for screening for early palliative care interventions. It has been studied primarily in dialysis and cancer patients and has been demonstrated to have a strong association with risk of death. We set out to test it in a more diverse primary care population.